



ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

CNPJ/MF No. 12.104.241/0004-02

NIRE 35.300.493.699

Publicly Traded Company

MATERIAL FACT

Oncoclínicas do Brasil Serviços Médicos S.A. (B3: ONCO3) (“Company” or “Oncoclínicas”), pursuant to Article 157, paragraph 4, of Law No. 6,404/76 and CVM Resolution No. 44, dated August 23, 2021, hereby informs its shareholders and the market, further to the Material Fact disclosed on August 14, 2025, that it continues to evaluate the possibility of implementing a potential capital increase through a private subscription of shares issued by the Company (“Potential Private Capital Increase”).

As disclosed in the Material Fact dated August 14th, 2025, the purpose of the Potential Private Capital Increase would be to strengthen the Company’s capital structure, in order to reduce its leverage and improve its financial indicators. Accordingly, the Potential Private Capital Increase may be structured to allow for the payment of new shares in cash or through the contribution of credits against the Company and/or its subsidiaries (including debentures, commercial notes, and other bank indebtedness).

The Company is also evaluating the granting of subscription warrants as an additional benefit to shareholders who participate in the Potential Private Capital Increase.

The Company further informs that it has engaged Rothschild & Co Brasil Ltda., as financial advisor, and Spinelli Advogados, as legal advisor, for the structuring of the Potential Private Capital Increase.

As of this date, there has been no decision, confirmation, or corporate approval regarding the effective implementation of the Potential Private Capital Increase, nor any definition of its final structure. The effective implementation of the Potential Private Capital Increase, as well as the determination of its terms and conditions, will depend on obtaining the necessary corporate approvals, market conditions, national and international political and macroeconomic conditions, the interest of shareholders, and other factors beyond the Company’s control.

This notice does not constitute a public offering of shares or any other securities of the Company in any jurisdiction.

The Company will keep its shareholders and the market duly informed of any developments or resolutions on the matter, in accordance with applicable legislation.



São Paulo, September 9th, 2025

Cristiano Affonso Ferreira de Camargo
Investor Relations Executive Officer
ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.